| Literature DB >> 31726013 |
Darryl Abrams1,2, Matthieu Schmidt3,4, Tài Pham5,6,7, Jeremy R Beitler1,2, Eddy Fan5,8, Ewan C Goligher5,8, James J McNamee9,10, Nicolò Patroniti11,12, M Elizabeth Wilcox5,8, Alain Combes3,4, Niall D Ferguson5,8, Danny F McAuley9,10, Antonio Pesenti13,14, Michael Quintel15, John Fraser16,17, Carol L Hodgson18,19, Catherine L Hough20, Alain Mercat21, Thomas Mueller22, Vin Pellegrino23, V Marco Ranieri24, Kathy Rowan25, Kiran Shekar16,17, Laurent Brochard5,6, Daniel Brodie1,2.
Abstract
Ventilator-induced lung injury remains a key contributor to the morbidity and mortality of acute respiratory distress syndrome (ARDS). Efforts to minimize this injury are typically limited by the need to preserve adequate gas exchange. In the most severe forms of the syndrome, extracorporeal life support is increasingly being deployed for severe hypoxemia or hypercapnic acidosis refractory to conventional ventilator management strategies. Data from a recent randomized controlled trial, a post hoc analysis of that trial, a meta-analysis, and a large international multicenter observational study suggest that extracorporeal life support, when combined with lower Vt and airway pressures than the current standard of care, may improve outcomes compared with conventional management in patients with the most severe forms of ARDS. These findings raise important questions not only about the optimal ventilation strategies for patients receiving extracorporeal support but also regarding how various mechanisms of lung injury in ARDS may potentially be mitigated by ultra-lung-protective ventilation strategies when gas exchange is sufficiently managed with the extracorporeal circuit. Additional studies are needed to more precisely delineate the best strategies for optimizing invasive mechanical ventilation in this patient population.Entities:
Keywords: acute respiratory distress syndrome; extracorporeal carbon dioxide removal; extracorporeal life support; extracorporeal membrane oxygenation; ventilator-induced lung injury
Mesh:
Substances:
Year: 2020 PMID: 31726013 DOI: 10.1164/rccm.201907-1283CI
Source DB: PubMed Journal: Am J Respir Crit Care Med ISSN: 1073-449X Impact factor: 21.405